Uncategorized

The loss of special government employee status for four members of the CDC’s Advisory Committee on Immunization Practices follows the resignation of ACIP co-lead Lakshmi Panagiotakopoulos, who left in protest of a controversial change in COVID-19 recommendations for healthy children and pregnant women.

Avidity has been given the go-ahead by the FDA to request accelerated approval of delpacibart braxlosiran—potentially the first disease-modifying treatment for facioscapulohumeral muscular dystrophy—with an application in the second half of 2026.

A federal judge awarded triple damages after a jury found Biosense Webster withheld support to hospitals that bought reprocessed catheters.

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin injection MET-233i showed promising weight-loss over about eight months.

Merck’s enlicitide decanoate significantly lowered low-density lipoprotein cholesterol in two Phase III trials, unlocking what BMO Capital Markets called a “multi-billion dollar opportunity” for the pharma.

After a major shareholder pushed back, Keros is returning half of its capital to investors in a move that Guggenheim analysts called “a positive step forward.”

Employers added 30,000 hospital jobs, 29,000 ambulatory healthcare services roles and 6,000 skilled nursing positions last month, according to the report. 

The chronic condition management company’s debut comes weeks after another digital health company, Hinge Health, went public. The IPOs are a “promising bellwether” for the sector, one expert said.

Empaveli reduced proteinuria by 68% versus placebo in glomerulopathy and glomerulonephritis, an effect that was sustained through one year of follow-up.

  Según un estudio publicado por la Revista Colombiana de Cancerología, aproximadamente 44 mil personas fallecen cada año a causa del cáncer en Colombia. Esta cifra refleja la urgencia de seguir explorando nuevas alternativas terapéuticas. En este contexto, …